应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AMGN 安进
盘前交易 03-28 05:52:11 EDT
286.30
+4.53
+1.61%
盘前
288.05
+1.75
+0.61%
05:06 EDT
最高
286.82
最低
282.55
成交量
225.62万
今开
284.22
昨收
281.77
日振幅
1.52%
总市值
1,534亿
流通市值
1,530亿
总股本
5.36亿
成交额
6.44亿
换手率
0.42%
流通股本
5.34亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
安进上涨1.23%,报285.23美元/股
金融界 · 00:16
安进上涨1.23%,报285.23美元/股
安进上涨1.22%,报279.53美元/股
金融界 · 03-26 03:46
安进上涨1.22%,报279.53美元/股
医药行业周报:安进/百济神州双抗疗法在中国启动3期临床
太平洋证券股份... · 03-26 00:00
医药行业周报:安进/百济神州双抗疗法在中国启动3期临床
押注“停药不反弹”!医药巨头安进的减肥药新战略
华尔街见闻 · 03-25
押注“停药不反弹”!医药巨头安进的减肥药新战略
安进上涨1.22%,报276.38美元/股
金融界 · 03-21
安进上涨1.22%,报276.38美元/股
安进下跌1.31%,报272.37美元/股
金融界 · 03-14
安进下跌1.31%,报272.37美元/股
安进上涨1.21%,报276.15美元/股
金融界 · 03-09
安进上涨1.21%,报276.15美元/股
安进(AMGN.US)KRAS抑制剂在中国启动3期临床 一线治疗非小细胞肺癌
智通财经 · 03-08
安进(AMGN.US)KRAS抑制剂在中国启动3期临床 一线治疗非小细胞肺癌
资料盒-诺和诺德为肥胖症大片药物的竞争带来新的竞争者
Reuters · 03-07
资料盒-诺和诺德为肥胖症大片药物的竞争带来新的竞争者
安进下跌1.22%,报275.98美元/股
金融界 · 03-06
安进下跌1.22%,报275.98美元/股
安进下跌1.31%,报273.83美元/股
金融界 · 03-01
安进下跌1.31%,报273.83美元/股
资料盒-制药商加大力度开拓肥胖症药物的蓬勃市场
Reuters · 02-28
资料盒-制药商加大力度开拓肥胖症药物的蓬勃市场
BUZZ-Viking Therapeutics 公司的减肥药在中期试验中获得成功,安进公司股价下跌
Reuters · 02-28
BUZZ-Viking Therapeutics 公司的减肥药在中期试验中获得成功,安进公司股价下跌
隔夜美股全复盘(2.24)| 美股三大股指分化,二手车电商平台Carvana大涨32%,去年净利润达到创纪录的1.5亿美元,指引乐观
格隆汇 · 02-24
隔夜美股全复盘(2.24)| 美股三大股指分化,二手车电商平台Carvana大涨32%,去年净利润达到创纪录的1.5亿美元,指引乐观
安进(AMGN.US)减肥药AMG 133国内启动I期临床试验
智通财经 · 02-23
安进(AMGN.US)减肥药AMG 133国内启动I期临床试验
卓和药业1.1类创新中药九味止咳口服液获批上市,AZ、安进、三生等新药临床获受理
医药经济报 · 02-21
卓和药业1.1类创新中药九味止咳口服液获批上市,AZ、安进、三生等新药临床获受理
安进下跌5.06%,报300.07美元/股
金融界 · 02-08
安进下跌5.06%,报300.07美元/股
安进盘中异动 股价大跌5.00%报300.28美元
自选股智能写手 · 02-08
安进盘中异动 股价大跌5.00%报300.28美元
BUZZ-Arrowhead Pharma 第一季度亏损超预期,业绩下滑
Reuters · 02-07
BUZZ-Arrowhead Pharma 第一季度亏损超预期,业绩下滑
加载更多
公司概况
公司名称:
安进
所属市场:
NASDAQ
上市日期:
--
主营业务:
安进公司是一家生物技术公司。该公司探索、开发、制造及销售人类治疗药品。该公司通过人类治疗药品业务运营。该公司销售的药品包括:Neulasta(pegfilgrastim),Aranesp(darbepoetin alfa)及EPOGEN(epoetin alfa)等促红细胞生成剂,Sensipar/Mimpara(cinacalcet),XGEVA(denosumab),Prolia(denosumab),NEUPOGEN(filgrastim),和Vectibix (panitumumab)、Nplate(romiplostim)及Corlanor(ivabradine)等。该公司专注于研发用于治疗肿瘤及血液病、心血管病、炎症、骨骼病、肾脏病及神经疾病等严重疾病的人类药物。该公司研发的处于第III阶段的产品包括用于发作性偏头痛的Erenumab,骨髓增生异常综合征的Aranesp,急性淋巴细胞白血病的BLINCYTO和转移性黑色素瘤的IMLYGIC。
发行价格:
--
{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":286.3,"timestamp":1711569600000,"preClose":281.77,"halted":0,"volume":2256188,"hourTrading":{"tag":"盘前","latestPrice":288.05,"preClose":286.3,"latestTime":"05:06 EDT","volume":414,"amount":119139.98436,"timestamp":1711616804400},"delay":0,"floatShares":534350480,"shares":535918901,"eps":12.49,"marketStatus":"盘前交易","marketStatusCode":1,"change":4.53,"latestTime":"03-28 05:52:11 EDT","open":284.22,"high":286.82,"low":282.55,"amount":643785286.54352,"amplitude":0.015154,"askPrice":288.99,"askSize":1,"bidPrice":287.84,"bidSize":22,"shortable":3,"etf":0,"ttmEps":12.49,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1711632600000},"adr":0,"listingDate":423288000000,"adjPreClose":286.3,"adrRate":0,"dividendRate":0.029759,"preHourTrading":{"tag":"盘前","latestPrice":288.05,"preClose":286.3,"latestTime":"05:06 EDT","volume":414,"amount":119139.98436,"timestamp":1711616804400},"postHourTrading":{"tag":"盘后","latestPrice":286.4,"preClose":286.3,"latestTime":"19:58 EDT","volume":116377,"amount":33318653.4395,"timestamp":1711583896343},"volumeRatio":0.8261795417185048},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"2422948485","title":"安进上涨1.23%,报285.23美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422948485","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422948485?lang=zh_cn&edition=full","pubTime":"2024-03-28 00:16","pubTimestamp":1711556211,"startTime":"0","endTime":"0","summary":"3月28日,安进(AMGN)盘中上涨1.23%,截至00:16,报285.23美元/股,成交1.94亿美元。财务数据显示,截至2023年12月31日,安进收入总额281.9亿美元,同比增长7.09%;归母净利润67.17亿美元,同比增长2.52%。大事提醒:4月25日,安进将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/28001640024984.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422578607","title":"安进上涨1.22%,报279.53美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422578607","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422578607?lang=zh_cn&edition=full","pubTime":"2024-03-26 03:46","pubTimestamp":1711396005,"startTime":"0","endTime":"0","summary":"3月26日,安进(AMGN)盘中上涨1.22%,截至03:46,报279.53美元/股,成交4.49亿美元。财务数据显示,截至2023年12月31日,安进收入总额281.9亿美元,同比增长7.09%;归母净利润67.17亿美元,同比增长2.52%。大事提醒:4月25日,安进将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/26034639987179.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422687793","title":"医药行业周报:安进/百济神州双抗疗法在中国启动3期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2422687793","media":"太平洋证券股份...","top":-1,"share":"https://www.laohu8.com/m/news/2422687793?lang=zh_cn&edition=full","pubTime":"2024-03-26 00:00","pubTimestamp":1711382400,"startTime":"0","endTime":"0","summary":"行业要闻:近日,中国药物临床试验登记与信息公示平台官网显示,安进和百济神州共同启动了一项国际多中心(含中国)3 期临床研究,以评价局限期小细胞肺癌放化疗后进行Tarlatamab 治疗的有效性和安全性,该药为一款靶向DLL3 和CD3 的双特异性T 细胞衔接蛋白,百济神州拥有该药的中国商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261129288b63975c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261129288b63975c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422593557","title":"押注“停药不反弹”!医药巨头安进的减肥药新战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2422593557","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2422593557?lang=zh_cn&edition=full","pubTime":"2024-03-25 14:24","pubTimestamp":1711347841,"startTime":"0","endTime":"0","summary":"减肥药“双雄”会变成“三巨头”吗?","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/b4190284-a744-4e30-933d-b6d62db254d7.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/b4190284-a744-4e30-933d-b6d62db254d7.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3711219","is_publish_highlight":false,"gpt_icon":0},{"id":"2421931044","title":"安进上涨1.22%,报276.38美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421931044","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421931044?lang=zh_cn&edition=full","pubTime":"2024-03-21 22:27","pubTimestamp":1711031231,"startTime":"0","endTime":"0","summary":"3月21日,安进(AMGN)盘中上涨1.22%,截至22:27,报276.38美元/股,成交7930.01万美元。财务数据显示,截至2023年12月31日,安进收入总额281.9亿美元,同比增长7.09%;归母净利润67.17亿美元,同比增长2.52%。大事提醒:4月25日,安进将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/21222739945895.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419660058","title":"安进下跌1.31%,报272.37美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419660058","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419660058?lang=zh_cn&edition=full","pubTime":"2024-03-14 22:02","pubTimestamp":1710424934,"startTime":"0","endTime":"0","summary":"3月14日,安进(AMGN)盘中下跌1.31%,截至22:02,报272.37美元/股,成交4940.51万美元。财务数据显示,截至2023年12月31日,安进收入总额281.9亿美元,同比增长7.09%;归母净利润67.17亿美元,同比增长2.52%。大事提醒:4月25日,安进将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/14220239857511.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418061294","title":"安进上涨1.21%,报276.15美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2418061294","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2418061294?lang=zh_cn&edition=full","pubTime":"2024-03-09 00:31","pubTimestamp":1709915507,"startTime":"0","endTime":"0","summary":"3月9日,安进(AMGN)盘中上涨1.21%,截至00:31,报276.15美元/股,成交1.98亿美元。财务数据显示,截至2023年12月31日,安进收入总额281.9亿美元,同比增长7.09%;归母净利润67.17亿美元,同比增长2.52%。大事提醒:3月6日,安进2023季度分配每1股派2.25美元股息,除权除息日2024-05-16,派息日2024-06-07。4月25日,安进将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/09003139788899.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417708835","title":"安进(AMGN.US)KRAS抑制剂在中国启动3期临床 一线治疗非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2417708835","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2417708835?lang=zh_cn&edition=full","pubTime":"2024-03-08 15:10","pubTimestamp":1709881847,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月8日,中国药物临床试验登记与信息公示平台官网公示,安进已经启动一项国际多中心(含中国)3期临床研究,旨在评估KRAS抑制剂sotorasib联合铂类双药化疗。用于PD-L1阴性且KRAS p.G12C阳性的IV期或晚期IIIB/C期非鳞状非小细胞肺癌患者一线治疗的有效性和安全性。本次安进在中国启动的是一项3期、多中心、随机、开放标签研究,针对的适应症为PD-L1阴性、KRAS p.G12C阳性的晚期/转移性NSCLC的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1083484.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417768805","title":"资料盒-诺和诺德为肥胖症大片药物的竞争带来新的竞争者","url":"https://stock-news.laohu8.com/highlight/detail?id=2417768805","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417768805?lang=zh_cn&edition=full","pubTime":"2024-03-07 20:45","pubTimestamp":1709815533,"startTime":"0","endTime":"0","summary":"诺和诺德公司在8月份报告了 一项大型研究的数据 ,该数据显示Wegovy对心血管也有明显的益处 。Wegovy与诺和诺德的糖尿病药物Ozempic使用相同的活性成分,于2021年获得批准。诺和诺德将在完成对康泰伦特的收购后收购这些工厂。有关这种药物与人体相互作用的数据预计将于明年公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417749424","title":"安进下跌1.22%,报275.98美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2417749424","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2417749424?lang=zh_cn&edition=full","pubTime":"2024-03-06 04:44","pubTimestamp":1709671462,"startTime":"0","endTime":"0","summary":"3月6日,安进(AMGN)盘中下跌1.22%,截至04:44,报275.98美元/股,成交5.26亿美元。财务数据显示,截至2023年12月31日,安进收入总额281.9亿美元,同比增长7.09%;归母净利润67.17亿美元,同比增长2.52%。大事提醒:4月25日,安进将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/06044439743938.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2416509600","title":"安进下跌1.31%,报273.83美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2416509600","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2416509600?lang=zh_cn&edition=full","pubTime":"2024-03-01 04:55","pubTimestamp":1709240113,"startTime":"0","endTime":"0","summary":"3月1日,安进(AMGN)盘中下跌1.31%,截至04:55,报273.83美元/股,成交6.48亿美元。财务数据显示,截至2023年12月31日,安进收入总额281.9亿美元,同比增长7.09%;归母净利润67.17亿美元,同比增长2.52%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/01045539691217.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2414385781","title":"资料盒-制药商加大力度开拓肥胖症药物的蓬勃市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2414385781","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414385781?lang=zh_cn&edition=full","pubTime":"2024-02-28 02:15","pubTimestamp":1709057743,"startTime":"0","endTime":"0","summary":"Wegovy与诺和诺德的糖尿病药物Ozempic使用相同的活性成分,于2021年获得批准。有关这种药物与人体相互作用的数据预计将于明年公布。罗氏表示,新收购的候选药物已完成早期试验,准备在三个试验阶段中的第二个阶段进行人体试验。西兰制药 丹麦西兰制药公司 和勃林格殷格翰公司的实验性肥胖症治疗药物在本周三进行的一项中期试验中取得了高达14.9%的减重 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414388825","title":"BUZZ-Viking Therapeutics 公司的减肥药在中期试验中获得成功,安进公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2414388825","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414388825?lang=zh_cn&edition=full","pubTime":"2024-02-28 01:19","pubTimestamp":1709054390,"startTime":"0","endTime":"0","summary":" 2月27日 - ** 正在开发减肥药的制药商安进 股价下跌2.6%,至278.9美元,拖累蓝筹股道琼斯指数<.DJI ** 规模较小的肥胖症药物开发商Viking Therapeutics的 实验性药物VK2735在一项中期研究中帮助患者实现了 \"显著 \"的体重减轻。** 安进公司将于今年晚些时候公布其主要注射减肥候选药物 , MariTide 的中期试验结果。** Truist Securities 公司分析师 Joon Lee 说,Viking 公司的数据可能会 \"对安进公司在肥胖症方面的期望造成压力\"。** 在美国上市的诺和诺德 股价下跌1.4%,报121.8美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413274915","title":"隔夜美股全复盘(2.24)| 美股三大股指分化,二手车电商平台Carvana大涨32%,去年净利润达到创纪录的1.5亿美元,指引乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=2413274915","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2413274915?lang=zh_cn&edition=full","pubTime":"2024-02-24 08:45","pubTimestamp":1708735501,"startTime":"0","endTime":"0","summary":"美股三大股指分化,二手车电商平台Carvana大涨32%,去年净利润达到创纪录的1.5亿美元,指引乐观","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/696325","is_publish_highlight":false,"gpt_icon":0},{"id":"2413733833","title":"安进(AMGN.US)减肥药AMG 133国内启动I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2413733833","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2413733833?lang=zh_cn&edition=full","pubTime":"2024-02-23 15:42","pubTimestamp":1708674167,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,近日,据CDE临床试验登记与信息公示平台显示,安进AMG 133国内启动I期临床试验,旨在评估在中国肥胖或超重受试者中,单次皮下给药后AMG 133的药代动力学、安全性和耐受性。据Insight数据库显示,AMG 133于2020年7月在美国首次启动临床,针对肥胖患者。在国内,鸿运华宁GMA106与AMG133机制相似。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1075608.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413443984","title":"卓和药业1.1类创新中药九味止咳口服液获批上市,AZ、安进、三生等新药临床获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2413443984","media":"医药经济报","top":-1,"share":"https://www.laohu8.com/m/news/2413443984?lang=zh_cn&edition=full","pubTime":"2024-02-21 20:02","pubTimestamp":1708516928,"startTime":"0","endTime":"0","summary":"Tremelimumab已于今年10月获FDA批准上市,用于与度伐利尤单抗联用一线治疗肝癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022120054487a8f447&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022120054487a8f447&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409919205","title":"安进下跌5.06%,报300.07美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2409919205","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2409919205?lang=zh_cn&edition=full","pubTime":"2024-02-08 03:03","pubTimestamp":1707332635,"startTime":"0","endTime":"0","summary":"2月8日,安进(AMGN)盘中下跌5.06%,截至03:03,报300.07美元/股,成交15.7亿美元。财务数据显示,截至2023年12月31日,安进收入总额281.9亿美元,同比增长7.09%;归母净利润67.17亿美元,同比增长2.52%。大事提醒:2月6日,安进2023财年年报归属股东应占溢利67.17亿美元,同比增长2.52%,基本每股收益12.56美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/02/08030339491658.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2409029203","title":"安进盘中异动 股价大跌5.00%报300.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2409029203","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2409029203?lang=zh_cn&edition=full","pubTime":"2024-02-08 03:01","pubTimestamp":1707332462,"startTime":"0","endTime":"0","summary":"北京时间2024年02月08日03时01分,安进股票出现波动,股价急速下挫5.00%。截至发稿,该股报300.28美元/股,成交量511.068万股,换手率0.96%,振幅4.77%。安进股票所在的制药行业中,整体涨幅为1.77%。指引方面,公司预计2024年全年营收为324亿至338亿美元,分析师预期为327亿美元;调整后每股收益为18.90至20.30美元,分析师预期为20.02美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240208030102791019ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240208030102791019ad&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409222518","title":"BUZZ-Arrowhead Pharma 第一季度亏损超预期,业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2409222518","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409222518?lang=zh_cn&edition=full","pubTime":"2024-02-07 22:09","pubTimestamp":1707314977,"startTime":"0","endTime":"0","summary":" 2月7日 - ** 药物开发商Arrowhead Pharmaceuticals 股价盘前下跌5.7%至31.3美元** Arrowhead报告称, ,第一季度 净亏损为1.24美元/股,分析师预计为亏损82美分/股--LSEG数据** ARWR 的收入比去年同期骤降 94%,降至 360 万美元。** 9月至12月的收入主要来自合作伙伴葛兰素史克 和武田 ,而去年同期 的收入来自强生公司的杨森部门、武田、Horizon和安进 。** 截至12月31日,Arrowhead公司拥有5820万美元的现金和现金等价物、 ** 截至周二收盘,该公司股价在过去 12 个月中下跌了 ~1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":0.0485},{"period":"1month","weight":-0.0002},{"period":"3month","weight":-0.0075},{"period":"6month","weight":0.0653},{"period":"1year","weight":0.2005},{"period":"ytd","weight":-0.006}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0975},{"period":"6month","weight":0.2238},{"period":"1year","weight":0.3225},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安进公司是一家生物技术公司。该公司探索、开发、制造及销售人类治疗药品。该公司通过人类治疗药品业务运营。该公司销售的药品包括:Neulasta(pegfilgrastim),Aranesp(darbepoetin alfa)及EPOGEN(epoetin alfa)等促红细胞生成剂,Sensipar/Mimpara(cinacalcet),XGEVA(denosumab),Prolia(denosumab),NEUPOGEN(filgrastim),和Vectibix (panitumumab)、Nplate(romiplostim)及Corlanor(ivabradine)等。该公司专注于研发用于治疗肿瘤及血液病、心血管病、炎症、骨骼病、肾脏病及神经疾病等严重疾病的人类药物。该公司研发的处于第III阶段的产品包括用于发作性偏头痛的Erenumab,骨髓增生异常综合征的Aranesp,急性淋巴细胞白血病的BLINCYTO和转移性黑色素瘤的IMLYGIC。","yearOnYearQuotes":[{"month":1,"riseRate":0.634146,"avgChangeRate":0.032606},{"month":2,"riseRate":0.463415,"avgChangeRate":-0.003118},{"month":3,"riseRate":0.512195,"avgChangeRate":0.019593},{"month":4,"riseRate":0.475,"avgChangeRate":-0.000427},{"month":5,"riseRate":0.525,"avgChangeRate":0.022711},{"month":6,"riseRate":0.5,"avgChangeRate":0.004307},{"month":7,"riseRate":0.756098,"avgChangeRate":0.052175},{"month":8,"riseRate":0.609756,"avgChangeRate":0.00518},{"month":9,"riseRate":0.536585,"avgChangeRate":0.003724},{"month":10,"riseRate":0.536585,"avgChangeRate":0.021341},{"month":11,"riseRate":0.634146,"avgChangeRate":0.022436},{"month":12,"riseRate":0.658537,"avgChangeRate":0.050861}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}